NO923910L - Farmasoeytiske forbindelser - Google Patents

Farmasoeytiske forbindelser

Info

Publication number
NO923910L
NO923910L NO92923910A NO923910A NO923910L NO 923910 L NO923910 L NO 923910L NO 92923910 A NO92923910 A NO 92923910A NO 923910 A NO923910 A NO 923910A NO 923910 L NO923910 L NO 923910L
Authority
NO
Norway
Prior art keywords
alkyl
phenyl
optionally substituted
hydroxy
carboxy
Prior art date
Application number
NO92923910A
Other languages
English (en)
Other versions
NO923910D0 (no
NO301587B1 (no
Inventor
Colin Peter Dell
Colin William Smith
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919121358A external-priority patent/GB9121358D0/en
Priority claimed from GB929213058A external-priority patent/GB9213058D0/en
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Publication of NO923910D0 publication Critical patent/NO923910D0/no
Publication of NO923910L publication Critical patent/NO923910L/no
Publication of NO301587B1 publication Critical patent/NO301587B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/80Dibenzopyrans; Hydrogenated dibenzopyrans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/92Naphthopyrans; Hydrogenated naphthopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO923910A 1991-10-09 1992-10-08 Fenylsubstituerte nafto£1,2-b| pyraner NO301587B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919121358A GB9121358D0 (en) 1991-10-09 1991-10-09 Pharmaceutical compounds
GB929213058A GB9213058D0 (en) 1992-06-19 1992-06-19 Pharmaceutical compounds

Publications (3)

Publication Number Publication Date
NO923910D0 NO923910D0 (no) 1992-10-08
NO923910L true NO923910L (no) 1993-04-13
NO301587B1 NO301587B1 (no) 1997-11-17

Family

ID=26299655

Family Applications (1)

Application Number Title Priority Date Filing Date
NO923910A NO301587B1 (no) 1991-10-09 1992-10-08 Fenylsubstituerte nafto£1,2-b| pyraner

Country Status (22)

Country Link
US (1) US5284868A (no)
EP (1) EP0537949B1 (no)
JP (1) JPH05194477A (no)
KR (1) KR100228841B1 (no)
CN (1) CN1034938C (no)
AT (1) ATE167859T1 (no)
AU (1) AU658003B2 (no)
CA (1) CA2079428A1 (no)
CZ (1) CZ281688B6 (no)
DE (1) DE69226060T2 (no)
DK (1) DK0537949T3 (no)
ES (1) ES2117035T3 (no)
FI (1) FI924551A (no)
HU (1) HU218916B (no)
IL (1) IL103356A (no)
MX (1) MX9205714A (no)
MY (1) MY111368A (no)
NO (1) NO301587B1 (no)
NZ (1) NZ244627A (no)
PH (1) PH30659A (no)
RU (1) RU2071472C1 (no)
TW (1) TW221292B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203497D0 (en) * 1992-02-19 1992-04-08 Lilly Industries Ltd Pharmaceutical compounds
EP0599514A3 (en) * 1992-11-18 1994-07-06 Lilly Industries Ltd Pyranoquinoline derivatives as inhibitors of cell proliferation.
GB9306062D0 (en) * 1993-03-24 1993-05-12 Lilly Industries Ltd Pharmaceutical compounds
EP0619314A1 (en) * 1993-04-09 1994-10-12 Eli Lilly And Company 4-Phenyl-4H- naphtho(2,1-b)pyran derivatives and their pharmaceutical use
WO1995008289A2 (en) * 1993-09-16 1995-03-30 Scimed Life Systems, Inc. Percutaneous repair of cardiovascular anomalies and repair compositions
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
ATE302599T1 (de) * 1996-05-24 2005-09-15 Angiotech Pharm Inc Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
IL119069A0 (en) 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
AU781986B2 (en) * 1999-11-05 2005-06-23 Cytovia, Inc. Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
US7053117B2 (en) * 2001-05-16 2006-05-30 Cytovia, Inc. Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6858607B1 (en) 2001-05-16 2005-02-22 Cytovia, Inc. 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
US7015328B2 (en) 2001-05-16 2006-03-21 Cytovia, Inc. Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US7528164B2 (en) * 2002-05-16 2009-05-05 Cytovia, Inc. Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP1513515A2 (en) * 2002-05-16 2005-03-16 Cytovia, Inc. Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20040127519A1 (en) * 2002-12-12 2004-07-01 Pharmacia Corporation Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
US20040127511A1 (en) * 2002-12-12 2004-07-01 Pharmacia Corporation Tricyclic aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
US20080194636A1 (en) * 2004-09-09 2008-08-14 Howard Florey Institute Of Experimental Physiology And Medicine Enzyme Inhibitors and Uses Thereof
EP2532390B1 (en) * 2005-02-16 2016-08-17 Md Bioalpha Co., Ltd. Pharmaceutical composition for liver diseases.
US20080183282A1 (en) * 2006-03-09 2008-07-31 Saul Yedgar Use of lipid conjugates for the coating of stents and catheters
WO2009065169A1 (en) 2007-11-19 2009-05-28 Howard Florey Institute Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof
EA015364B1 (ru) * 2009-03-18 2011-06-30 Учреждение Российской Академии Наук Институт Элементоорганических Соединений Им. А.Н. Несмеянова Ран (Инэос Ран) 6,6'-диизопропил-8,8'-диметил-2,2'-динитро-3,3'-бис(трифторметил)- 3н,3'н-[9,9']ди[бензо(f)хроменил]-5,10,5',10'-тетраол, обладающий противоопухолевой и противогрибковой активностью, и способ его получения
CN103328463B (zh) 2010-11-12 2018-04-03 德国癌症研究中心 作为Wnt通路拮抗剂的色烯衍生物及其类似物
AU2012335665A1 (en) 2011-11-10 2014-07-03 Memorial Sloan-Kettering Cancer Center Treatment of ovarian cancer with 2-amino-4H-naphtho[1,2-B]pyran-3-carbonitriles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU724509A1 (ru) * 1978-09-21 1980-03-30 Пермский государственный фармацевтический институт Способ получени 2-ароил-3н- нафто 2,1-в пиранонов-3
WO1989009769A1 (en) * 1988-04-14 1989-10-19 Yamanouchi Pharmaceutical Co., Ltd. Substance q-2819 and process for its preparation

Also Published As

Publication number Publication date
FI924551A (fi) 1993-04-10
FI924551A0 (fi) 1992-10-08
CZ281688B6 (cs) 1996-12-11
NO923910D0 (no) 1992-10-08
CA2079428A1 (en) 1993-04-10
IL103356A (en) 1998-02-22
KR100228841B1 (ko) 1999-11-01
MX9205714A (es) 1993-04-01
EP0537949B1 (en) 1998-07-01
CN1073437A (zh) 1993-06-23
DK0537949T3 (da) 1999-02-15
AU658003B2 (en) 1995-03-30
NO301587B1 (no) 1997-11-17
TW221292B (no) 1994-02-21
US5284868A (en) 1994-02-08
DE69226060T2 (de) 1998-11-19
EP0537949A1 (en) 1993-04-21
RU2071472C1 (ru) 1997-01-10
CZ303592A3 (en) 1993-12-15
ES2117035T3 (es) 1998-08-01
PH30659A (en) 1997-09-16
JPH05194477A (ja) 1993-08-03
AU2621692A (en) 1993-04-22
DE69226060D1 (de) 1998-08-06
ATE167859T1 (de) 1998-07-15
MY111368A (en) 1999-12-31
HU9203183D0 (en) 1992-12-28
HUT62281A (en) 1993-04-28
NZ244627A (en) 1994-12-22
IL103356A0 (en) 1993-03-15
HU218916B (hu) 2000-12-28
KR930007931A (ko) 1993-05-20
CN1034938C (zh) 1997-05-21

Similar Documents

Publication Publication Date Title
NO923910D0 (no) Farmasoeytiske forbindelser
CO5150224A1 (es) Compuestos de triazol y su utilizacion
FI913782A (fi) Isoxazolderivat.
NO983099D0 (no) Nye retrovirale proteasehemmere
RS49984B (sr) Inhibitori azot (ii) oksid sintaze
DK0524180T3 (da) Smagsmaskering af ibuprofen ved fluid bedovertrækning
DK0641325T3 (da) Inhibitorer af retroviral protease
DK0386557T3 (da) Fremgangsmåde til bekæmpelse af svampe bortset fra hos mennesker og dyr
FI942094A (fi) Kollagenaasin inhibiittori
HRPK20040293B3 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
ATE312085T1 (de) Pestizid wirkende triazin-derivate
MY109777A (en) Pharmaceutical compounds therewith
DK0743938T3 (da) Substituerede spiroforbindelser til behandling af inflammation
ATE167855T1 (de) Propensäure derivate verwendbar als fungizide
DK0639173T3 (da) Visse 2- (2'-methyl-3', 4'-trisubstitueret benzoyl) -1,3-cyklohexandioner
DK0417746T3 (da) N-Azabicyclo(3.3.0)octanamider af aromatiske syrer
ID24231A (id) Derivat-derivat 5-disubstitusi-1,2,4-tiadiazolil yang menghambat angiogenesis
MX9204939A (es) Inhibidores 5-bis-aminometilen-1,3-dioxan-4,6-diona n,n',n'-trisubstituidas, de la acil coenzima a: colesterol-aciltransferasa.
SU1531429A1 (ru) 0-[(тетрагидрофурил-2-)метил]-n-[(3'-изоцианато-4'-метил)фенил]карбамат в качестве ингибитора коррозионно-механического разрушения трубных сталей
TH17774EX (th) อนุพันธ์ 1,3-ออกซาซิน-4-โอนชนิดใหม่ สารฆ่าวัชพืชที่มีอนุพันธ์เหล่านี้และสารมัธยันตร์สำหรับการเตรียอนุพันธ์เหล่านี้
CO5210866A1 (es) Inhibidores de cinasas, de pirrolotriazina
IT1162465B (it) Procedimento per proteggere materiali cheratinici da insetti ed agenti nonche' composti barbiturici per esso
TH6968A (th) ไตรสับสทิทิวด์ 1,3,5-ไตรเอซีน 2,4,6-ไตรโอน
TH6968EX (th) ไตรสับสทิทิวด์ 1,3,5-ไตรเอซีน 2,4,6-ไตรโอน

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN APRIL 2003